Successful collaborations between three Mexican institutions in the study of dyslipidemia, obesity and diabetes;Colaboraciones exitosas entre tres instituciones mexicanas en el estudio de las dislipidemias, la obesidad y la diabetes

Gaceta Medica de Mexico

Volumn 143, Issue 5, 2007, Pages 355-364

  Aguilar Salinas, Carlos Alberto ^a   Canizales Quinteros, Samuel ^b   Rojas Martínez, Rosalba ^c   García García, Eduardo ^a   Olaiz Fernández, Gustavo ^c   Gómez Pérez, Francisco J ^a   Tusié Luna, María Teresa ^b  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Diabetes; HDL cholesterol; Metabolic syndrome; Obesity

Indexed keywords

ADULT; AGED; ALLELE; DIABETES MELLITUS; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE LOCUS; GENETIC ANALYSIS; GENETIC RISK; HEALTH CARE ORGANIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEXICO; MOLECULAR EPIDEMIOLOGY; OBESITY; REVIEW; RISK ASSESSMENT; ARTICLE; COOPERATION; GENETICS; METABOLIC SYNDROME X; MIDDLE AGED; PUBLIC RELATIONS;

ADULT; AGED; COOPERATIVE BEHAVIOR; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HUMANS; INTERINSTITUTIONAL RELATIONS; MALE; METABOLIC SYNDROME X; MEXICO; MIDDLE AGED; OBESITY;

EID: 42949164155     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Aguilar-Salinas CA, Gómez-Pérez FJ. La declaración de Acapulco. Rev Invest Clin 2006;58:71-77.
2. Lindstrõm J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson J, Hemio K, Hamalainen H, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention:follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-1679.
3. Strong K, Mathers C, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save. Lancet 2005;366:1578-1582.
4. Epping-Jordan, Galea G, Tukuitonga C, Beaglehole R. Preventing chronic diseases: taking stepwise action. Lancet 2005;366:1667-1671.
5. Soriguer F, Morcillo S, Cardona F, Rojo-Martínez G, de la Cruz-Almaraz M, Ruiz de Adana M de L, et al. Pro12Ala polymorphism of the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J Nutr 2006;136:2325-2330.
6. Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, et al. Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Arch Med Res 2006;37:736-743.
7. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881-885.
8. Aguilar-Salinas CA, Gómez-Pérez FJ, Lerman I, Pérez O, Posadas C. Diagnóstico y tratamiento de las dislipidemias. Postura de la Sociedad Mexicana de Nutrición y Endocrinología. Rev Endocrinol Nutr 2004;12:7-41.
9. Aguilar-Salinas CA, Olaiz G, Valles V, Ríos JM, Gómez-Pérez FJ, Rull JA, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nation wide survey. J Lipid Res 2001;42:1298-1307.
10. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Franco A, Olaiz G, et al. Características de los casos con dislipidemias mixtas en un estudio de población: resultados de la Encuesta Nacional de Enfermedad Crónicas. Salud Publica Mex 2002;44:546-553.
11. Rojas R, Aguilar-Salinas CA, Gómez-Pérez FJ, Valles V, Franco A, Olaiz G, et al. Applicability of the National Cholesterol Education Program III (NCEP-III) Guidelines for treatment of dyslipidemia in a non-Caucasian population: a Mexican Nation-Wide Survey. Rev Invest Clin 2005;57:28-37.
12. Valles V, Aguilar-Salinas CA, Gómez-Pérez FJ, Rojas R, Franco A, Olaiz G, et al. Apolipoprotein B and AI distribution in the Mexican urban adults: Results of a Nation-Wide Survey. Metabolism 2002;51:560-568.
13. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, García E, Valles V, Ríos-Torres JM, et al. Early onset type 2 diabetes in a Mexican, population-based, nation-wide survey. Am J Med 2002;113:569-574.
14. Aguilar-Salinas CA, Mehta R, Rojas R, Gómez-Pérez FJ, Olaiz G, Rull JA. Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues. Curr Diabetes Rev 2005:1:145-158.
15. Rull JA, Aguilar-Salinas CA, Rojas R, Ríos-Torres JM, Gómez-Pérez FJ, Olaiz G. Epidemiology of type 2 diabetes in México. Arch Med Res 2005;36:188-196.
16. Aguilar-Salinas CA, Rojas R, Ríos-Torres JM, Gómez-Pérez FJ, Olaiz G, Rull JA. The metabolic syndrome: a concept in evolution. Arch Med Res 2005:36:223-231.
17. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Ríos-Torres JM, Franco A, et al. High prevalence of the metabolic syndrome in México. Arch Med Res 2004;35:76-81.
18. Villarreal-Molina MT, Aguilar-Salinas CA, Rodríguez-Cruz M, Riaño D, Villalobos-Comparán M, Flores-Dorantes MT, et al. The ABCA1 R230C variant affects HDL cholesterol levels and body mass index in the Mexican population: association with obesity and obesity-related co-morbidities. Diabetes 2007:56:1881-1887.
19. Robles L, Huerta A, Ordóñez ML, Canizales S, Díaz A, Gutiérrez R, et al. Mutational and genetic linkage analyses of autosomal dominant hypercholesterolemia in Mexico: evidence for further genetic heterogeneity. Arch Med Res 2006;37:102-108.
20. Aguilar-Salinas CA, Rojas R, González-Villalpando C, Gómez-Pérez FJ, Mehta R, Olaiz G, et al. Design and validation of a population-based definition of the metabolic syndrome. Diabetes Care 2006:2420-2426.
21. Aguilar Salinas CA, Huertas A, Tusié MT, Gómez- Pérez FJ, Rull JA Hiperlipidemia familiar combinada. Rev Endocrinol Nutr 2002;10:58-62.
22. González-Villalpando C, Stern MP, Valdez R, Mitchell B, Haffner S. Niveles de lípidos sanguíneos y riesgo aterogénico en población urbana abierta. Rev Invest Clin 1993;45:127-132.
23. González-Villalpando C, Stern MP, Arredondo PB, Martínez DS, Haffner SM. Undiagnosed hypercholesterolemia: a serious health challenge. The Mexico City Diabetes Study. Arch Med Res 1996;27:19-23.
24. Robles-Osorio L, Ordóñez ML, Aguilar-Salinas CA, Aurón-Gómez M, Tusié-Luna MT, Gómez-Pérez FJ, et al. Familial hypercholesterolemia due to a ligand-defective apolipoprotein B-100. First case-report in a Mexican family. Arch Med Res 2003;34:70-75.
25. Canizales-Quinteros S, Aguilar-Salinas CA, Reyes-Rodríguez E, Riba L, Rodríguez-Torres M, Ramírez-Jiménez S, et al. Locus on chromosome 6p linked to elevated HDL-C serum levels, and to protection against premature atherosclerosis in a kindred with familial hypercholesterolemia. Circulation Res 2003:92:569-576.
26. Canizales-Quinteros S, Aguilar-Salinas CA, Huertas-Vázquez A, Ordóñez-Sánchez ML, Rodríguez-Torres M, Venturas-Gallegos JL, et al. A novel ARH splice site mutation in a Mexican kindred with autosomal recessive hypercholesterolemia and evidence of possible interaction between the 1p35 and 15q25-26 loci in the expression of the disease. Human Genetics 2005;116:114-120.
27. Aguilar-Salinas CA, Zamora M, Gómez- Díaz RA, Mehta R, Gómez-Pérez FJ, Rull JA. Familial combined hyperlipidemia: controversial aspects of its diagnosis and pathogenesis. Sem Vasc Med 2004:4:203-209.
28. Del Rincón-Jarero JP, Aguilar-Salinas CA, Guillén-Pineda LE, Gómez-Pérez FJ, Rull JA. Lack of agreement between the plasma lipid based criteria and the apoprotein B for the diagnosis of familial combined hyperlipidemia (FCHL) in members of FCHL kindreds. Metabolism 2002;51:218-224.
29. Aguilar-Salinas CA, Barrett HP, Pulai J, Zhu X, Schonfeld G. Description of a kindred with familial combined hyperlipidemia with unusual kinetic abnormalities of the apolipoprotein B containing lipoproteins. Effects of pravastatin therapy. Arterios Thromb Vasc Biol 1997;17:72-82.
30. Huertas-Vázquez A, del Rincón-Jarero JP, Canizales-Quinteros S, Vega-Hernández G, Riba L, Ramírez- Jiménez S, et al. Replication of linkage of familial combined hyperlipidemia to chromosome 1q21-q23 in Mexican families. Ann Human Genet 2004;68:419-427.
31. Huertas-Vázquez A, Aguilar Salinas C, Lusis A, Cantor R, Canizales A, Lee J, et al. Familial combined hyperlipidemia in Mexicans. Association with upstream transcription factor 1 and linkage on chromosome 16q24.1. Arterios Thromb Vasc Biol 2005;25:1985-1991.
32. Weissglas D, Huertas-Vázquez A, Canizalez S, Suviolahti E, Lee J, Aguilar-Salinas CA, et al. Common hepatic nuclear factor 4 alpha variants are associated with high serum lipid levels and the metabolic syndrome. Diabetes 2006;55:1970-1977.
33. Aguilar-Salinas CA, Díaz- Polanco A, Quintana E, Macías M, Arellano A, Ramírez E, et al. Genetic factors play an important role in the pathogenesis of hyperlipidemia post-transplantation. Am J Kidney Dis 2002;40:169-177.
34. Tamez R, Aguilar-Salinas CA, Gómez-Pérez FJ. Prevalencia de las dislipidemias primarias en pacientes con diabetes sobrevivientes de un evento coronario. Rev Endocrinol Nutr 2004;12:42-45.
35. Mehta R, Loredo B, Sañudo ME, Hernández-Jiménez S, Rodríguez-Carranza SI, Gómez-Pérez FJ, et al Epidemiología de las anormalidades metabólicas en pacientes con infección por VIH. Rev Invest Clin 2004:56:209-221.
36. Lara-Esqueda A, Aguilar-Salinas CA, Velázquez O, Gómez-Pérez FJ, Rosas M, Mehta R, et al. The body mass index is a less sensitive tool for detecting cases with obesity related co-morbidities in short stature subjects. Int J Obes Relat Metab Disord 2004;28:1443-1450.
37. Probst MC, Thumann H, Aslanidis C, Langmann T, Buechler C, Patsch W,et al. Screening for functional sequence variations and mutations in ABCA1. Atherosclerosis 2004;175:269-279.
38. Wang J, Burnett JR, Near S, Young K, Zinman B, Hanley AJG, et al. Common and rare ABCA1 variants affecting plasma HDL cholesterol. Arterios Thromb Vasc Biol 2000;20:1983-1989.
39. Canizales-Quinteros S, Aguilar-Salinas CA, Ortiz-López G, Rodríguez-Cruz M, Villarreal-Molina MT, Coral-Vázquez R, et al. Association of PPAR gamma 2 Pro12Ala variant with larger body mass index in Mestizo and Amerindian populations of Mexico. Human Biol 2007;78:111-117.
40. Olaiz G, Rojas R, Barquera S, Shamah T, Aguilar-Salinas C, Cravioto P, et al. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos. Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México. 2003.
41. Aguilar-Salinas CA, Velásquez-Monroy O, Gómez- Pérez FJ, González-Chávez A, Lara-Esqueda A, Molina-Cuevas V, et al. Characteristics of the patients with type 2 diabetes in México: results from a large population-based, nation-wide survey. Diabetes Care 2003:26:2021-2026.
42. González-Villalpando C, Stern MP, Villalpando E, Hazuda H, Haffner S, Lisci E. Prevalencia de diabetes e intolerancia a la glucosa en una población urbana de nivel económico bajo. Rev Invest Clin 1992;44:321-328.
43. Stern MP, González-Villalpando C, Mitchell B, Villalpando E, Haffner S, Hazuda H. Genetic and environmental determinants of type 2 diabetes in Mexico City and San Antonio. Diabetes 1992;41:484-492.
44. Gómez-Pérez FJ, Aguilar-Salinas CA, López- Alvarenga JC, Guillén LE, Wong B, Rull-Rodrigo JA. Lack of agreement between the World Health Organization category of impaired glucose tolerance and the American Diabetes Association category of impaired fasting glucose Diabetes Care 1998;21:1886-1888.
45. Gómez-Pérez FJ, Aguilar-Salinas CA, Vázquez- Chávez C, Fanghänel-Salmón G, Gallegos-Martínez J, Gómez-Díaz R, et al. Further insight on the hypoglycemic and non-hypoglycemic effects of troglitazone 400 or 600 mg/day: Effects on the VLDL and HDL lipoprotein particle distribution. Metabolism 2002;51:44-51.
46. Gómez-Pérez FJ, Fanghänel-Salmon G, Barbosa J, Montes-Villarreal J, Berry RA, Warsi G, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-134.
47. Gómez-Pérez FJ, Rull JA, Díes H, Rodríguez-Rivera JG, González-Barranco J, Lozano-Castaneda O. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain 1985; 23:395-400.
48. Canizales-Quinteros S, Huertas-Vázquez A, Riba- Ramírez L, Monroy-Guzmán A, Domínguez-López A, Romero-Hidalgo S, et al. Identifying different susceptibility loci associated with early onset diabetes and cardiovascular disease in Mexican families. Gac Med Mex 2005;141:115-122.
49. Navalón-García K, Mendoza-Alcántar L, Díaz-Vargas ME, Martínez- Godínez MA, Reyna-Garfias H, Aguilar-Salinas CA, et al. HNF-1alpha G574S is a functional variant with decreased transactivation activity. Diabetes Med 2006;23:1295-1300.
50. Aguilar-Salinas CA, Reyes-Rodríguez E, Ordóñez- Sánchez ML, Arellano Torres M, Ramírez-Jiménez S, Domínguez-López A, et al. Early-onset type 2 diabetes: metabolic and genetic characterizarion in Mexican population. J Clin Endoc Metab 2001;86:220-226.
51. Domínguez-López A, Miliar-García A, Segura-Kato YX, Riba L, Esparza-López R, Ramírez-Jiménez S, et al. Mutations in MODY genes are not common cause of early-onset type 2 diabetes in Mexican families. JOP 2005; 10:238-245.
52. del Bosque-Plata L, Aguilar-Salinas CA, Tusié-Luna MT, Ramírez-Jiménez S, Rodríguez-Torres M, Aurón- Gómez M, et al. Association of the calpain-10 gene with type 2 diabetes mellitus in a Mexican population. Mol Genet Metab 2004;81:122-126.